The Effects of Metformin Monotherapy and Combination of Metformin and Glibenclamide Therapy on the Expression of , , and Genes in Peripheral Blood Mononuclear Cells of Type 2 Diabetic Patients

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2022 Jun 8

PMID 35673478

Authors

Hashem Hosseinipoor

Seyed Yousef Kariminejad

Moharram Salehi

Mozhdeh Heidari

Mohammad Taghi Goodarzi

Mohammad Hossein Karimi

Affiliations

Soon will be listed here.

Abstract

Purpose: Although metformin is the first-line treatment of type 2 diabetes mellitus (T2DM), a few studies have evaluated the benefits of monotherapies (metformin) versus combination therapy (metformin and glibenclamide) for treatment of T2DM patients. The present study aimed to evaluate the effect of monotherapy with metformin compared to combination therapy with metformin and glibenclamide on the expression of , , and genes.

Methods: EightyT2DM patients and 40 healthy individuals participated in this case-control study. The patients in the treatment group were divided into two groups who received either metformin alone (n = 40) or metformin in combination with glibenclamide (n = 40). FBS, HbA1c, and fructosamine were measured. The expression of , , and genes in PBMC of all subjects were assessed using real-time PCR.

Results: gene expression in both treatment groups was significantly lower than the control (P < 0.05). gene expression was significantly reduced in the combination of metformin and glibenclamide treated group compared to metformin group (P < 0.05). Additionally, the expression of and genes in both treatment groups was higher than that of the control group (P < 0.05). The expression of and genes in metformin and glibenclamide treated group were higher than the metformin group (P < 0.05).

Conclusion: Combination therapy (metformin and glibenclamide) showed stronger effect on repression of the gene and activation of and genes compared to monotherapy (metformin); therefore, it can be concluded that combination therapy may have more protective effects on the T2DM patients. No significant correlation was observed between HbA1c and , , and genes expression.

Citing Articles

Sirtuins and Their Implications in the Physiopathology of Gestational Diabetes Mellitus.

Zgutka K, Tkacz M, Grabowska M, Mikolajek-Bedner W, Tarnowski M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861104 PMC: 11768332. DOI: 10.3390/ph18010041.

References

Cuadrado A, Manda G, Hassan A, Alcaraz M, Barbas C, Daiber A . Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacol Rev. 2018; 70(2):348-383. DOI: 10.1124/pr.117.014753. View

Mafauzy M . Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002; 58(1):45-53. DOI: 10.1016/s0168-8227(02)00104-3. View

Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S . Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res. 2012; 44(12):891-5. DOI: 10.1055/s-0032-1321878. View

Ramasamy R, Vannucci S, Yan S, Herold K, Yan S, Schmidt A . Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology. 2005; 15(7):16R-28R. DOI: 10.1093/glycob/cwi053. View

Schmidt A, Stern D . Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep. 2000; 2(5):430-6. DOI: 10.1007/s11883-000-0082-4. View

Ayers D, Baron B, Hunter T . miRNA Influences in NRF2 Pathway Interactions within Cancer Models. J Nucleic Acids. 2015; 2015:143636. PMC: 4546755. DOI: 10.1155/2015/143636. View

Cohen M, Shea E, Chen S, Shearman C . Glycated albumin increases oxidative stress, activates NF-kappa B and extracellular signal-regulated kinase (ERK), and stimulates ERK-dependent transforming growth factor-beta 1 production in macrophage RAW cells. J Lab Clin Med. 2003; 141(4):242-9. DOI: 10.1067/mlc.2003.27. View

Rich S . Diabetes: Still a geneticist's nightmare. Nature. 2016; 536(7614):37-8. DOI: 10.1038/nature18906. View

Tosi F, Muggeo M, Brun E, Spiazzi G, Perobelli L, Zanolin E . Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomized, double-blind, comparative study. Metabolism. 2003; 52(7):862-7. DOI: 10.1016/s0026-0495(03)00101-x. View

10.

Leibiger I, Berggren P . Sirt1: a metabolic master switch that modulates lifespan. Nat Med. 2006; 12(1):34-6. DOI: 10.1038/nm0106-34. View

11.

Kitada M, Kume S, Kanasaki K, Takeda-Watanabe A, Koya D . Sirtuins as possible drug targets in type 2 diabetes. Curr Drug Targets. 2013; 14(6):622-36. DOI: 10.2174/1389450111314060002. View

12.

Cheng J, Huang C, Liu I, Tzeng T, Chang C . Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes. 2006; 55(3):819-25. DOI: 10.2337/diabetes.55.03.06.db05-0934. View

13.

Herold K, Moser B, Chen Y, Zeng S, Yan S, Ramasamy R . Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J Leukoc Biol. 2007; 82(2):204-12. DOI: 10.1189/jlb.1206751. View

14.

Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V . Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000; 49(12):2063-9. PMC: 2995498. DOI: 10.2337/diabetes.49.12.2063. View

15.

Ishii H, Jirousek M, Koya D, Takagi C, Xia P, Clermont A . Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996; 272(5262):728-31. DOI: 10.1126/science.272.5262.728. View

16.

Hou X, Xu S, Maitland-Toolan K, Sato K, Jiang B, Ido Y . SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem. 2008; 283(29):20015-26. PMC: 2459285. DOI: 10.1074/jbc.M802187200. View

17.

Gu J, Ye S, Wang S, Sun W, Hu Y . Metformin inhibits nuclear factor-κB activation and inflammatory cytokines expression induced by high glucose via adenosine monophosphate-activated protein kinase activation in rat glomerular mesangial cells in vitro. Chin Med J (Engl). 2014; 127(9):1755-60. View

18.

Tabish S . Is Diabetes Becoming the Biggest Epidemic of the Twenty-first Century?. Int J Health Sci (Qassim). 2011; 1(2):V-VIII. PMC: 3068646. View

19.

Trinanes J, Salido E, Fernandez J, Rufino M, Gonzalez-Posada J, Torres A . Type 1 diabetes increases the expression of proinflammatory cytokines and adhesion molecules in the artery wall of candidate patients for kidney transplantation. Diabetes Care. 2012; 35(2):427-33. PMC: 3263898. DOI: 10.2337/dc11-1665. View

20.

Palmer S, Mavridis D, Nicolucci A, Johnson D, Tonelli M, Craig J . Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. JAMA. 2016; 316(3):313-24. DOI: 10.1001/jama.2016.9400. View